There is a significant unmet need for optimized treatment in rhabdomyolysis. There are few prospective interventional studies on treatment for rhabdomyolysis, a condition which affects diverse and underrepresented populations at a higher rate. While steroids are often used off-label, a systematic study has not yet been initiated, and steroids have not been yet considered in as a consideration to standard care guidelines.
The hypothesis is that patients who receive dexamethasone in addition to standard care versus placebo and standard care will have improvement in pain, length of hospital stay, and decrease in kidney complications.
Diagnosis of rhabdomyolysis defined as creatine kinase> 5000 with trauma excluded
Ability of parents/patients to understand and the willingness to sign a written informed consent document.
Patients ages 12 and older will sign written assent
Already taking systemic steroids.
Inability to comply with study instructions.
Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant women.
Parallel
Dexamethasone
DrugSteroid five day treatment
Placebo
DrugPlacebo control group
Length of Stay
Number of days Length of Stay in Each Group
Muscle breakdown
Creatinine Kinase trend comparison between groups
Renal complications
Bun/ Creatinine
Quantitative Pain Outcomes
EHR pain scores
Click on the lead sponsor to view all of their trials.
